[1] Lennon VA, Kryzer TJ, Pittock SJ, et al.IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel[J]. J Exp Med, 2005, 202(4): 473-477. [2] Wingerchuk DM, Banwell B, Bennell JL, et al.International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J]. Neurology, 2015, 85(2): 177-189. [3] 王月彩,檀国军,王程晓. 神经脊髓炎谱系疾病的治疗现状及进展[J]. 临床荟萃, 2016, 31(10): 1155-1160. [4] Liao MF, Chang KH, Lye RK, et al.Comparison between the cranial magnetic resonance imaging features of neuromyelitis optica spectrum disorder versus multiple sclerosis in Taiwanese patients[J]. BMC Neurol, 2014, 14: 218. [5] Wingerchuk DM, Banwel LB, Bennrtt JL, et al.International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J]. Neurology, 2015, 85(2): 177-189. [6] Waters P, Woodhall M, O'Connor KC, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease[J]. Neurol Neuroimmunol Neuroinflamm, 2015, 2(3): e89. [7] Höftberger R, Sepulveda M, Armangue T, et al.Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease[J]. Multiple Sclerosis, 2015, 21(7): 866-874. [8] Papadopoulos MC, Bennett JI, Verkman AS.Treatment of neuromyelitis optica: state-of-the-art and emerging therapies[J]. Nat Rev Neu, 2014, 10(9): 493-506. [9] Kimbrough DJ, Fujihara K, Jacob A, et al.Treatment of neuromyelitis optica: review and recommendations[J]. Mult Scler Relat Disord, 2012, 1(4): 180-187. [10] Torres J, Pruitt A, Balcer L, et al.Analysis of the treatment of neuromyelitis optica[J]. J Neurol Sci, 2015, 351(1-2): 29-36. [11] Yamasaki R, Matsushita T, Fukazawa T, et al.Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica[J]. Mult Scler, 2015, 22(10): 1337-1348. [12] 叶静. 视神经脊髓炎[M]//刘广志. 多发性硬化. 北京:北京大学医学出版社, 2012: 245-246. [13] Kim SH, Kim W, Huh SY, et al.Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels[J]. J Clin Neurol, 2013, 9(1): 36-42. [14] Lim YM, Pyun SY, Kang BH, et al.Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders[J]. Mult Scler, 2013, 19(9): 1216-1218. [15] Viswanathan S, Wong AHY, Quek AML, et al.Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica[J]. J Neuroimmunol, 2015, 282: 92-96. [16] Kleiter I, Gold R.Present and future therapies in neuromyelitis optica spectrum disorders[J]. Neurotherapeutics, 2015, 13(1): 70-83. [17] Wei Q, Kermode AG, Rui L, et al.Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica[J]. J Clin Neuro Soci, 2015, 22(7): 1178-1182. [18] Chen H, Zhang Y, Shi Z, et al.The efficacy and tolerability of mycophenolate mofetil in treating neuromyelitis optica and neuromyelitis optica spectrum disorder in western China[J]. Clin Neuropharmacol, 2016, 39(2): 81-87. [19] Rommer PS, Dörner T, Freivogel K, et al.Safety and clinical outcomes of rituximab treatment in patients with multiple sclerosis and neuromyelitis optica: experience from a National Online Registry (GRAID)[J]. J Neuroimmune Pharmacol, 2015, 11(1): 1-8. [20] Trebst C, Jarius S, Berthele A, et al.Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group(NEMOS)[J]. J Neurol, 2014, 261(1): 1-16. [21] Yang CS, Yang L, Li T, et al.Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica[J]. Neurology, 2013, 81(8): 710-713. [22] Kitley J, Elsone L, George J, et al.Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin -4 antibodies[J]. J Neurol Neurosurg Psychiatry, 2013, 84: 918-921. [23] Vodopivec I, Matiello M, Prasad S.Treatment of neuromyelitis optica[J]. Curr Opin Ophthalmol, 2015, 26(6): 476-483. [24] Palace J, Leite MI, Nairne A, et al.Interferon Beta treatment in neuromyelitis optica:increase in relapses and aquaporin 4 antibody titers[J]. Arch Neurol, 2010, 67(8): 1016-1017. [25] Miyazaki K, Abe Y, Iwanari H, et al.Establishment of monoclonal antibodies against the extracellular domain that block binding of NMO-IgG to AQP4[J]. J Neuroimmunol, 2013, 260(1-2): 107-116. [26] Wang H, Wang K, Wang C, et al.Cerebrospinal fluid highmobility group box protein 1 in neuromyelitis optica and multiple sclerosis[J]. Neuroimmunomodulation, 2013, 20(2): 113-118. [27] Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, et al.Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter[J]. Ann Neurol, 2012, 72(1): 53-64. [28] Ayzenberg I, Kleiter I, Schröder A, et al.Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy[J]. JAMA Neurol, 2013, 70(3): 394-397. [29] Kieseier BC, Stüve O, Dehmel T, et al.Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses[J]. JAMA Neurol, 2013, 70(3): 390-393. [30] Patrick A, Jamma L, Chris A, et al.Resolution of aquaporin-4 antibodies in a woman with neuromyelitis optica treated with human autologous stem cell transplant[J]. J Clin Neurosci, 2015, 22: 1215-1217. [31] Pittock SJ, Lennon VA, McKcon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study[J]. Lancet Neurol, 2013, 12(6): 554-562. [32] Uzawa A, Mori M, Uchida T, et al.Increased levels of CSF CD59 in the long-term course of neuromyelitis optica[J]. Clin Chim Acta, 2016, 453: 131-133. [33] Saadoun S, Waters P, MacDonald C, et al. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain[J]. Ann Neurol, 2012, 71: 323-333. [34] Zhang H, Verkman AS.Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica[J]. J Clin Invest, 2013, 123(5): 2306-2316. [35] Kemp K, Redondo J, Hares K, et al.Oxidative injury in multiple sclerosis cerebellar grey matter[J]. Brain Res, 2016, 1642: 452-460. [36] Mealy MA, Shin K, John G, et al.Bevacizumab is safe in acute relapses of neuromyelitis optica[J]. Clin Exp Neuroimmunol, 2015, 6(4): 413-418. [37] Papadopoulos MC, Bennett JL, Verkman AS.Treatment of neuromyelitis optica: state-of-the-art and emerging therapies[J]. Nat Rev Neurol, 2014, 10(9): 493-506. |